Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy
Related Posts
Rana AI, Castillo-Mancilla J, Landovitz RJ. Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. Reply. N Engl J Med. 2026 May 14;394(19):1963-1964. doi:[...]
Cai A, Liu L, Feng Y, Zhou Y, Li L, Bozkurt B, Januzzi JL, Lam CSP, Fonarow GC, Pandey A, Zhou Z, Cheng Y, Bayes-Genis[...]
Patel KK, Maddahi J, Agostini D, Bax JJ, Beanlands RSB, Berman D, Dorbala S, Heller GV, Knuuti JM, Pelletier-Galarneau M, Tamaki N, Thompson D, Somer[...]